RT Journal Article SR Electronic T1 TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5489 OP 5495 DO 10.21873/anticanres.12882 VO 38 IS 9 A1 AKIRA TAKEUCHI A1 TETSUYA OGURI A1 YORIKO YAMASHITA A1 KAZUKI SONE A1 SATOSHI FUKUDA A1 OSAMU TAKAKUWA A1 TAKEHIRO UEMURA A1 KEN MAENO A1 KENSUKE FUKUMITSU A1 YOSHIHIRO KANEMITSU A1 HIROTSUGU OHKUBO A1 MASAYA TAKEMURA A1 YUTAKA ITO A1 AKIO NIIMI YR 2018 UL http://ar.iiarjournals.org/content/38/9/5489.abstract AB Background/Aim: To investigate whether TTF-1 expression predicts a beneficial response of non-squamous non-small-cell lung cancer (NS-NSCLC) patients to bevacizumab. Patients and Methods: We retrospectively screened 118 advanced NS-NSCLC patients who were treated with pemetrexed plus platinum derivatives alone (Bev(−)) or with bevacizumab (Bev(+)), and investigated the relationship between expression of TTF-1 and treatment outcomes. Results: Among the 92 TTF-1-positive patients, clinical outcomes in the Bev(+) group were significantly better than those in the Bev(−) group (response rate, 51.4% vs. 27.3%, p=0.027; median progression-free survival, 216 days vs. 137 days, p=0.012). Overall survival in the Bev(+) group tended to be longer than that in the Bev(−) group. However, the addition of bevacizumab to the standard treatment of 26 TTF-1-negative patients offered no clinical benefit. Conclusion: TTF-1 expression may serve as a predictive marker to identify patients who may benefit from the addition of bevacizumab to platinum doublet therapy.